Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial

Article ID	Journal	Published Year	Pages	File Type
5903345	Metabolism	2014	8 Pages	PDF

Abstract

These findings suggest that a non-renal mechanism (ie, beyond UGE) contributes to glucose lowering for canagliflozin 300Â mg, but not 150Â mg.

Keywords

SGLT1 PBO SGLT2 FPG C150 AUC standard deviation standard error Urinary glucose excretion sodium glucose co-transporter 2 Sulfonylurea body mass index BMI Coefficient of Variation adverse event confidence interval not applicable Fasting plasma glucose Metformin Clinical Research Center MET Area under the concentration-time curve UGE Placebo CRC Least squares Plasma glucose

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Endocrinology

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial

Authors

Peter Stein, Jolene K. Berg, Linda Morrow, David Polidori, Eunice Artis, Sarah Rusch, Nicole Vaccaro, Damayanthi Devineni,